Progress on Covalent Inhibition of KRAS(G12C)
- PMID: 26951837
- DOI: 10.1158/2159-8290.CD-16-0092
Progress on Covalent Inhibition of KRAS(G12C)
Abstract
Recent reports of small-molecule approaches to directly inhibit oncogenic KRAS(G12C) have invigorated the RAS research community by raising the possibility of drugging a protein that was long considered "undruggable." A new iteration of covalent compounds targeting the allosteric switch II pocket of KRAS(G12C) showed improved potency and selectivity and enabled studies demonstrating that KRAS(G12C) rapidly cycles its nucleotide substrate. This report illustrates the value of chemical probes in dissecting RAS biology and raises additional hope for development of viable pharmacologic strategies for directly targeting KRAS(G12C).
©2016 American Association for Cancer Research.
Comment on
-
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.Cancer Discov. 2016 Mar;6(3):316-29. doi: 10.1158/2159-8290.CD-15-1105. Epub 2016 Jan 6. Cancer Discov. 2016. PMID: 26739882
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous